Volume 17, Number 6—June 2011
Dispatch
Klebsiella pneumoniae Bacteremia and Capsular Serotypes, Taiwan
Table A1
Distribution and clinical characteristics of 225 patients with Klebsiella pneumoniae bacteremia caused by different serotypes, Taiwan*
| Characteristic | K1, n = 41 | K2, n = 37 | Non–K1/K2, n = 147 | Univariate analysis (K1 vs. non– K1/K2) |
Univariate analysis (K2 vs. non–K1/K2) |
|||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |||||
| Age, y | 61.8 ± 13.8 | 58.6 ± 15.1 | 62.2 ± 16.4 | 1.00 (0.98–1.02) | 0.88 | 0.99 (0.96–1.01) | 0.23 | |
| M:F | 26:15 | 24:13 | 95:52 | 0.95 (0.46–1.95) | 0.89 | 1.01 (0.58–2.15) | 0.98 | |
| Source of patients | ||||||||
| Emergency department | 36 (87.8) | 22 (59.5) | 75 (51.0) | 6.91 (2.57–18.60) | <0.001 | 1.41 (0.68–2.93) | 0.36 | |
| Ward | 5 (12.2) | 8 (21.6) | 47 (17.0) | 0.30 (0.11–0.80) | 0.017 | 0.59 (0.25–1.38) | 0.22 | |
| Intensive care unit | 0 | 7 (18.9) | 25 (32.0) | NA | NA | 1.14 (0.45–2.88) | 0.78 | |
| Severity of disease (McCabe classification) | ||||||||
| Nonfatal | 31 (75.6) | 24 (64.9) | 79 (53.7) | 2.67 (1.22–5.84) | 0.014 | 1.59 (0.75–3.36) | 0.23 | |
| Ultimately fatal | 7 (17.1) | 8 (21.6) | 50 (34.0) | 0.40 (0.17–0.97) | 0.041 | 0.54 (0.23–1.26) | 0.15 | |
| Rapidly fatal | 3 (7.3) | 5 (13.5) | 18 (12.3) | 0.57 (0.16–2.02) | 0.38 | 1.12 (0.39–3.24) | 0.84 | |
| Pittsburgh bacteremia score | 2.7 ± 3.1 | 5.0 ± 5.3 | 4.4 ± 4.7 | 0.90 (0.81–0.99) | 0.032 | 1.03 (0.95–1.10) | 0.50 | |
| Underlying illness, condition, or value | ||||||||
| Diabetes mellitus | 19 (46.3) | 14 (37.8) | 54 (36.7) | 1.49 (0.74–2.99) | 0.27 | 1.05 (0.50–2.21) | 0.90 | |
| End-stage renal disease | 1 (2.4) | 1 (2.7) | 8 (5.4) | 0.43 (0.05–3.58) | 0.44 | 0.48 (0.06–3.99) | 0.50 | |
| Heart disease | 4 (9.8) | 8 (21.6) | 33 (22.5) | 0.37 (0.12–1.12) | 0.08 | 0.95 (0.40–2.28) | 0.91 | |
| Stroke | 4 (9.8) | 3 (8.1) | 21 (14.3) | 0.65 (0.21–2.01) | 0.45 | 0.53 (0.15–1.88) | 0.33 | |
| Active malignancy | 5 (12.2) | 6 (16.2) | 29 (19.7) | 0.57 (0.20–1.57) | 0.27 | 0.79 (0.30–2.07) | 0.63 | |
| Liver cirrhosis | 4 (9.8) | 6 (16.2) | 23 (15.7) | 0.58 (0.19–1.79) | 0.35 | 1.04 (0.39–2.78) | 0.93 | |
| Surgery within 3 mo | 4 (9.8) | 8 (21.6) | 45 (30.6) | 0.25 (0.08–0.73) | 0.011 | 0.63 (0.27–1.47) | 0.28 | |
| CT within 3 mo | 2 (4.9) | 3 (8.1) | 16 (10.9) | 0.42 (0.09–1.91) | 0.26 | 0.72 (0.20–2.62) | 0.62 | |
| Creatinine level, mg/dL | 1.7 ± 1.9 | 1.6 ± 1.4 | 1.9 ± 2.0 | 0.93 (0.76–1.13) | 0.45 | 0.91 (0.73–1.14) | 0.42 | |
| Albumin level, g/dL† | 2.8 ± 0.6 | 2.7 ± 0.6 | 2.7 ± 0.7 | 1.13 (0.57–2.23) | 0.74 | 0.85 (0.43–1.71) | 0.65 | |
| Type of infection | ||||||||
| Primary bacteremia | 11 (26.8) | 12 (32.4) | 39 (26.5) | 1.02 (0.47–2.22) | 0.97 | 1.33 (0.61–2.90) | 0.47 | |
| Respiratory tract | 4 (9.8) | 6 (16.2) | 30 (20.4) | 0.42 (0.14–1.28) | 0.13 | 0.76 (0.29–1.98) | 0.57 | |
| Urinary tract | 2 (4.9) | 3 (8.1) | 30 (20.4) | 0.20 (0.05–0.88) | 0.033 | 0.34 (0.10–1.20) | 0.09 | |
| Biliary tract | 3 (7.3) | 3 (8.1) | 26 (17.7) | 0.37 (0.11–1.28) | 0.12 | 0.41 (0.12–1.44) | 0.16 | |
| Liver abscess | 19 (46.3) | 5 (13.5) | 6 (4.1) | 20.3 (7.31–56.40) | <0.001 | 3.67 (1.06–12.8) | 0.041 | |
| Intraabdominal | 1 (2.4) | 5 (13.5) | 8 (5.4) | 0.43 (0.05–3.58) | 0.44 | 2.72 (0.83–8.85) | 0.10 | |
| Catheter related | 0 | 0 | 6 (4.1) | NA | NA | NA | NA | |
| Soft tissue | 0 | 1 (2.7) | 2 (1.36) | NA | NA | 2.01 (0.18–22.83) | 0.57 | |
| Meningitis | 1 (2.4) | 2 (5.4) | 0 | NA | NA | NA | NA | |
| TTP, h | 14.4 ± 18.5 | 12.1 ± 12.1 | 13.1 ± 16.3 | 1.00 (0.99–1.02) | 0.65 | 1.00 (0.97–1.02) | 0.75 | |
| TTP<7 h | 6 (14.6) | 7 (18.9) | 32 (21.8) | 0.62 (0.24–1.59) | 0.32 | 0.84 (0.34–2.09) | 0.71 | |
| 14-d mortality rate | 4 (9.8) | 10 (27.0) | 35 (23.8) | 0.35 (0.12–1.04) | 0.058 | 1.19 (0.52–2.69) | 0.68 | |
| In-hospital mortality rate | 6 (14.6) | 16 (43.2) | 51 (34.7) | 0.32 (0.13–0.82) | 0.017 | 1.43 (0.70–2.99) | 0.34 | |
| ESBL producer | 0 | 0 | 4 (2.7) | NA | NA | NA (NA) | NA | |
| Effective empirical agent | 35 (85.4) | 36 (97.3) | 138 (93.9) | 0.38 (0.13–1.14) | 0.08 | 2.35 (0.29–19.14) | 0.43 | |
*Values are mean ± SD or no. (%) unless otherwise indicated. OR, odds ratio; CI, confidence interval; NA, not applicable; CT, computed tomography; TTP, time to positive blood culture; ESBL, extended-spectrum β-lactamase.
†For K1 group, 24 patients; for K2 group, 25 patients; for non–K1/K2 group, 93 patients.
